Key points from article :
In Alzheimer’s, nerve cells in the brain or peripheral nervous system lose function over time and ultimately die.
Psychedelics stimulate neurogenesis, provoke neuroplastic changes and reduce neuroinflammation - could treat neurodegenerative diseases.
Challenges with psychedelics are identifying effective dose without catalyzing aggressive behavior or worsening cognitive impairment.
Microdosing 5-MeO-DMT (intranasally) and psilocybin reduced neuroinflammation and increased neuroplasticity, thereby improving cognitive health.
Clinical trials yet to show significant therapeutic efficacy and long-term safety of microdosing.
An AI-driven psychedelic drug discovery company, April19 Discovery, to develop next generation psychedelic-inspired compounds.
“Representing a molecule in a machine, we generate novel molecules that are likely to have the interesting properties that you want,” said Richard Dallaway.
“AI-designed psychedelic compounds would ideally overcome issues in high- and low-dose treatments, as well as with fewer side-effects,” said Jáchym Fibír.
Psychedelics and AI could potentially outperform the medical field in treating age-related diseases.
